MedTrace Logo

L-carnitine for Reducing Cardio-metabolic Risk in Patients With Obstructive Sleep Apnea

NCT02645942 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-05-06

No results posted yet for this study

Summary

The investigators designed this intervention to investigate the potential role of L-C in lipid and carbohydrates metabolism (primary outcome) with precision noninvasively measurement of: central blood pressure, pulse wave velocity and peripheral arterial stiffness (secondary outcome) in OSA patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

L-carnitine

L-carnitine 1400 mg daily for 8 weeks

DIETARY_SUPPLEMENT

Placebo

Placebo daily for 8 weeks

Sponsors & Collaborators

  • Poznan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Paweł Bogdański, Ass Prof, MD · Poznan University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2020-12-31
Completion
2021-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02645942 on ClinicalTrials.gov